Magnesium sulphate ampoules — what they contain, how they are given and what matters beforehand

Magnesium is among the best-selling supplements in Romania, and the injectable form — magnesium sulphate in ampoules — is searched for separately, hundreds of times a month. This article explains what the ampoules contain and, more importantly, why with magnesium the order of the questions is different from other IV drips.

What the ampoules contain

The active substance is magnesium sulphate — on the leaflet, *magnesii sulfas*. It comes in ampoules, in packs such as boxes of 10 ampoules, at concentrations that differ between manufacturers.

The leaflet describes its action as antispasmodic, anticonvulsant and sedative, of short duration. Intravenous administration is slow, in medically determined doses, and in specific clinical situations — eclampsia, tetanus — the regimens are entirely different from those used to top up intake.

One thing worth saying plainly: the ampoules are not given undiluted and are not bought for self-administration. This is not a token precaution.

Which ampoules are authorised in Romania today

In the Medicines Nomenclature of the National Agency for Medicines (ANM, Romania's medicines regulator), updated on 11 September 2026, injectable magnesium sulphate is listed at a concentration of 200 mg/ml, in 10 ml ampoules — that is, 2 g of magnesium sulphate per ampoule: a solution for injection in boxes of 10 ampoules, dispensed on prescription, and a concentrate for solution for infusion of 2 g/10 ml, in boxes of 5 ampoules.

For comparison, the dose in our protocol, 1,500 mg, is less than the contents of a single 10 ml ampoule. This is not an accounting detail: it shows how concentrated an ampoule is and why it is diluted before it is given.

Why the rate matters

Magnesium given quickly into a vein causes a feeling of warmth, flushing and a fall in blood pressure. These are not exotic effects; they follow directly from the speed.

That is why the infusion is diluted and runs slowly — with us, 1500 mg over 40 minutes. The time is not a commercial choice; it is the very mechanism that keeps the administration comfortable and safe.

The part that matters most: your kidneys

This is where magnesium differs from almost every other intravenous protocol.

With glutathione, vitamin C or iron, the main risk we watch for is a hypersensitivity reaction — something that happens during administration. With magnesium, the main risk is accumulation.

Magnesium is cleared by the kidneys. In a person with normal kidney function an excess is rare, because the body gets rid of it efficiently. In kidney failure, however, it accumulates, and hypermagnesaemia — too much magnesium in the blood — shows up as:

• muscle weakness;
• a fall in blood pressure;
• nausea, confusion;
• in severe forms, breathing difficulties and heart disturbances.

Hypermagnesaemia is an absolute contraindication to giving any more magnesium.

Contraindications on the leaflet

• kidney failure;
• Addison's disease;
• barbiturate poisoning.

At the assessment we also check your current medicines — including laxatives and antacids that contain magnesium, because they add to your total intake and are a common cause of excess in people who use them often.

Beyond the leaflet: heart block, myasthenia, medicines

The short Romanian leaflet lists three contraindications. The US label for injectable magnesium sulphate, published on DailyMed, adds a few things worth knowing:

• heart block or damage to the heart muscle — parenteral administration is contraindicated;
• medicines that depress the nervous system — barbiturates, opioids, sleeping pills, anaesthetics — have an additive effect with magnesium;
• neuromuscular blockers used in anaesthesia — excessive neuromuscular blockade has been described;
• digoxin and other cardiac glycosides — extreme caution, because of the risk of conduction disturbances;
• pregnancy — continuous administration beyond 5–7 days can affect the baby's bones.

And myasthenia gravis. Magnesium reduces the release of acetylcholine at the junction between nerve and muscle — exactly the mechanism affected in myasthenia. Cases of acute respiratory failure after intravenous magnesium in people with myasthenia have been published, including recurring with each new dose.

What excess looks like, in the order it appears

The product label describes a clear sequence as blood magnesium rises: at low levels there is only flushing and sweating; at higher levels blood pressure falls; then the tendon reflexes weaken and disappear; at very high levels respiratory paralysis can occur, and heart block can occur at these levels or even lower.

That is why, in hospital, with large and repeated doses, the knee-jerk reflex is checked before each dose — its disappearance is an early sign of excess. The described antidote is intravenous calcium.

What to tell the doctor at the assessment

• whether you have kidney disease or have ever been told your kidney function is reduced;
• whether you have heart rhythm disturbances, a heart block or heart disease;
• whether you have myasthenia or another neuromuscular disease;
• whether you are pregnant;
• which medicines you take, including digoxin, sedatives, sleeping pills, and laxatives and antacids containing magnesium.

When the intravenous route makes sense

Oral magnesium works well for most people and, for background intake, it is the first option. We say so even though we give the other kind.

The limit comes with high doses: intestinal absorption is limited, and the unabsorbed surplus draws water into the gut. That is why the laxative effect appears before stores are saturated — a threshold that no oral dose gets past, whatever the form or quality of the product.

The intravenous route bypasses that threshold: the dose reaches the circulation fully and predictably. That is all that can be stated with certainty — that this translates into clinical benefit for a person without a specific problem is a separate claim, with a lower level of evidence.

Where intravenous magnesium has solid evidence — and why it is all in hospital

To be fair to the subject, it is worth saying where intravenous magnesium sulphate actually has good evidence. All of these situations are emergency or hospital settings, and none of them is something an IV drip clinic does:

• pre-eclampsia and eclampsia — the Magpie trial, published in The Lancet in 2002, in more than 10,000 women, showed that magnesium sulphate roughly halves the risk of eclampsia;
• an asthma attack that does not respond to initial treatment — a 2014 Cochrane review of 14 trials and 2,313 adults found that a single infusion of 1.2 or 2 g, given over 15–30 minutes on top of standard emergency treatment, reduces hospital admissions: by about seven for every 100 patients treated;
• acute hypomagnesaemia, especially with signs of tetany — an indication stated explicitly on the injectable product's label.

We list them precisely to make clear what a 1,500 mg infusion at the clinic is not: it is not a treatment for any of the situations above. Those need a hospital.

Where the evidence is weak: sleep, stress, tiredness

Magnesium is very often linked with sleep and stress. Here the data are much thinner. A 2021 systematic review found only three randomised trials, with 151 older adults with insomnia, all using oral magnesium. Time to fall asleep was on average about 17 minutes shorter than with placebo, but the authors rated the quality of the evidence as low or very low and said explicitly that the literature does not allow well-founded recommendations — while noting that oral magnesium is cheap and easy to obtain.

If that is the situation for oral magnesium, an infusion does not come with better evidence for sleep or stress. We say it plainly: a magnesium drip is not a sleeping pill, it does not “recharge” your energy and it does not fix tiredness that has another cause.

Magnesium in your blood test does not show everything

A useful detail if you have had blood tests: serum magnesium is an accessible test used to track changes, but it does not necessarily reflect the total amount of magnesium in the body — about 99% sits in bone, muscle and other tissues, and less than 1% circulates in the serum. A value within range does not by itself rule out a deficiency, and a value slightly outside it does not by itself make a diagnosis. Interpretation happens at the assessment, not from an article.

How we work at Synerva

Magnesium IV drip — 250 RON, magnesium sulphate 1500 mg, diluted, given slowly into a vein over 40 minutes, with monitoring throughout, after a medical assessment that includes kidney function.

Magnesium also appears in the Complex B forte protocol, alongside B complex, taurine and L-carnitine, and in Minerals & trace elements.

We do not sell ampoules and we do not recommend self-administration of injectables.

Sources

Magnesium sulphate ampoules — leaflet (Romanian) — composition, therapeutic action, method of administration, contraindications.

Magnesium: contraindications and precautions (Romanian) — including hypermagnesaemia and the situations in which it occurs.

Nomenclature of medicines for human use — ANM (Romanian medicines regulator) — the authorised magnesium sulphate ampoules, concentration, packs (version of 11 September 2026).

Magnesium Sulfate Injection 50% — US product label, DailyMed — indications, the contraindication in heart block, interactions, signs of magnesium toxicity.

Altman D et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial. Lancet, 2002 (PMID 12057549).

Kew KM et al. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database of Systematic Reviews, 2014 (PMID 24865567).

Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a Systematic Review & Meta-Analysis. BMC Complementary Medicine and Therapies, 2021 (PMID 33865376).

Jahnen-Dechent W, Ketteler M. Magnesium basics. Clinical Kidney Journal, 2012 (PMID 26069819) — the limits of serum magnesium and how magnesium is distributed in the body.

Jessop K. Intravenous magnesium sulfate inducing acute respiratory failure in a patient with myasthenia gravis. BMJ Case Reports, 2022 (PMID 35738845).

For information only. Doses and whether administration is appropriate are decided by the doctor, at the assessment.